WIN Begins SureDose Pen Cold Chain For HCP FAQ WinMitra Safety Info

Your once-weekly WIN journey starts here.

Semawin 0.25 mg pen Semawin 0.5 mg pen Semawin 1 mg pen Semawin 1.7 mg pen Semawin 2.4 mg pen

A SureDose™ Solution to WIN

SEMAWIN introduction film
Introduction film · 2:40

See how SEMAWIN fits one guided, once-weekly routine.

Watch the film
The basics

SEMAWIN is a once-weekly semaglutide designed to help improve glycemic control, support weight reduction, and promote cardio-renal-metabolic care.

Simple to use with the SureDose™ Pen, SEMAWIN works best alongside healthy eating, regular physical activity, and guidance from your healthcare professional.

Meet your SureDose™ Pen

SureDose Semawin pen parts: pen cap, outer & inner needle caps, needle, cartridge holder, paper tab, flow-check symbol, dose window, dose knob, injection button
SureDose™ Semawin pen

Designed for confidence. Engineered for convenience.

Compliant with ISO 11608 for pen-injector performance — consistent, low-force dosing across every strength.

SureDose Semawin pen designed for confidence and engineered for convenience: delivers the full dose in 6 seconds, consistent dose accuracy, colour-coded strengths, smooth low-force administration, ISO 11608 compliant
When to inject

The starting dose, on your day, at your hour.

0.25mg
The starting dose of Semawin, before any step-up.
Once-weekly
On the same day each week.
Anyhour
Morning or night, with or without food.
Know how to inject

Watch the short video to understand the 5 easy steps to inject.

1
Preparation

Wash your hands and prepare a clean injection site.

2
Flow Checking

Attach a fresh needle everytime.

3
Dose Selection

Dial your prescribed dose in the dose window.

4
Inject the Dose

Press and hold the button until the dose completes.

5
After Injection

Remove and dispose of the needle safely, then rotate the site.

SureDose™ cold chain
The journey of trust at 2°C–8°C

Every SEMAWIN pen travels with care before it becomes part of your WIN journey.

4.0°CIntegrity secure
Live · logged every 60s
Stage 1 of 6

Factory

Filled and sealed under controlled conditions.

5.0°CSealed at source
For healthcare professionals

SEMAWIN contains semaglutide, which offers WIN benefits.

W
Weight reduction1
I
Improved glycemic parameters2
N
Novel organ protection3,4,5

Intended for registered healthcare professionals

Clinical data, outcome statistics, and prescribing information are presented for professional reference only.

SEMAWIN Chronicle

Your questions, answered.

Everything you need to know about your once-weekly journey

How do I store the pen? +
  • Before first use: Store in a refrigerator (2°C–8°C). Do not freeze.
  • After first use: Store below 30°C, or in a refrigerator (2°C–8°C). Do not freeze.
Where do I inject? +

Give the injection just under the skin (subcutaneous). The best sites are the upper arm, the abdomen (at least 5 cm away from your belly button), and the thigh — rotate the site each time.

Best places to inject Semawin subcutaneously: upper arm, abdomen at least 5 cm from the belly button, and thigh
What if I miss a dose? +
  • If it’s been 5 days or less, take it as soon as you remember.
  • If it’s been more than 5 days, skip it and take your next dose on your regular scheduled day.
  • Do not take a double dose to make up for a missed dose.
Download the Chronicle
SEMAWIN Chronicle comic panel
WinMitra ecosystem

Because every WIN needs a Mitra.

Reminders, tracking, and support between visits, in one companion app.

Dose reminders Health tracking Diet support Exercise guidance Medicine availability
WinMitra app
Download WinMitra
Scan to download
WIN mascot
6

Seconds to WIN over CRM risk

In T2DM and obese patients, once-weekly Semawin precisely matches the innovator — in molecular design and in clinical outcomes.

Matches the innovator in design

Structural identity
Amino acid sequence
Comparable antibody formation

Matches the innovator in outcomes

Reduction in HbA1c
1.6%
Reduction in weight
10.4kg
Novel organ protection
26%
CV death, MI & stroke1
T2DM with ASCVD · median 2.1 years
24%
Kidney failure or kidney-related cause2
Median follow-up 3.4 years
29%
Resolution of MASH3
At week 72
Now approved for MASH in India4

*Data on file. 1. N Engl J Med 2016;375(19):1834–1844. 2. N Engl J Med 2024;391(2):109–121. 3. N Engl J Med 2025;392(21):2089–2099. 4. CDSCO approval. CV: cardiovascular · MI: myocardial infarction · MASH: metabolic dysfunction-associated steatohepatitis. For registered healthcare professionals; reductions vs comparator.

SureDose™ family

Five doses. One WIN journey.

Hover a pen — it turns to colour and its strength orbits into view.Swipe through each strength.

Semawin 0.25 mg SureDose pen
Semawin 0.5 mg SureDose pen
Semawin 1 mg SureDose pen
Semawin 1.7 mg SureDose pen
Semawin 2.4 mg SureDose pen
Support

Find your SEMAWIN representative.

Choose a state to see contact details
Important safety information

Use SEMAWIN safely.

What SEMAWIN is

SEMAWIN (semaglutide) is a once-weekly, prescription GLP-1 receptor agonist used alongside diet and activity for weight and glycemic management. Use it only as directed by your doctor.

Before you start

Tell your doctor about all your conditions and medicines — including any personal or family history of thyroid tumours (MTC / MEN 2), pancreatitis, gallbladder or kidney problems, and if you are pregnant, planning pregnancy, or breastfeeding.

Possible side effects

The most common are gastrointestinal — nausea, vomiting, diarrhoea, or constipation — and usually ease over time. Seek care for severe stomach pain, signs of an allergic reaction, or symptoms of low blood sugar when combined with other diabetes medicines.

Storage

Store between 2°C and 8°C; do not freeze. Keep out of the reach of children.

This is a summary and does not replace the full Prescribing Information. Report any side effects to your doctor. Download the full Prescribing Information.

Safety Info Start the WIN journey